Division of Medical Oncology, Mayo Clinic, Rochester, MN55905, USA.
Clin Colorectal Cancer. 2011 Dec;10(4):258-65. doi: 10.1016/j.clcc.2011.06.008. Epub 2011 Aug 5.
Over the last several decades advances in the management and treatment of patients with liver metastases from colorectal cancer (CRC) has changed a disease with a dismal prognosis to one with a potential for cure in some patients. Advances have been made through coordinated management of patients by surgeons, medical oncologists, radiologists, and other health care professionals coupled with advances in treatment options. Although these advances have clearly impacted patient outcomes, it is clear that the benefit of traditional surgical approaches and the use of cytoxic chemotherapy are reaching a plateau. Continued research to develop new and more active therapies, including targeted or biologic agents, is needed. This review discusses the advances made in management of patients with liver-limited metastatic disease.
在过去的几十年中，结直肠癌肝转移患者的管理和治疗取得了进展，使这种预后极差的疾病在某些患者中具有了治愈的可能。这些进展是通过外科医生、肿瘤内科医生、放射科医生和其他医疗保健专业人员共同协调患者管理，并结合治疗选择的进步来实现的。尽管这些进展明显影响了患者的结局，但传统手术方法和细胞毒性化疗的益处显然已达到平台期。需要继续研究以开发新的、更有效的治疗方法，包括靶向或生物制剂。本文讨论了肝转移疾病患者管理方面的进展。
